MyFinsight
Home
Blog
About
Contact
Proceeds from notes
payable
$995,000
Redemption of short term
investments
-$500,000
Net cash provided by
financing activities
$920,000
Net cash provided by
investing activities
$490,606
Canceled cashflow
$75,000
Canceled cashflow
$9,394
Net increase
(decrease) in cash, cash...
-$657,121
Canceled cashflow
$1,410,606
Unrealized gain from
changes in fair value of...
-$22,061,472
Advisory shares
committed for issuance
$8,113,318
Accounts payable and
accrued expenses
$2,134,541
Accretion on convertible
notes
$851,018
Stock based
compensation - option grants
$114,166
Depreciation & amortization
expense
$20,044
Non-cash digital asset
operating expenses
$8,726
Interest expense
$8,387
Operating lease liability
$2,122
Payment of issuance
costs
$75,000
Purchases of pp&e
$9,394
Net cash used in
operating activities
-$2,067,727
Canceled cashflow
$33,313,794
Net loss
-$35,059,852
Prepaid expenses and
other current assets
$273,390
Change in fair value of
derivative liability
$48,279
Back
Back
Cash Flow
Apimeds Pharmaceuticals US, Inc. (APUS)
Apimeds Pharmaceuticals US, Inc. (APUS)
source: myfinsight.com